Alto Neuroscience (NYSE: ANRO) expects cash to last through 2030, but quarterly loss widens

What happened

Alto Neuroscience, Inc. (NYSE: ANRO) expects its $319.8 million of cash to fund planned operations through 2030.

The balance includes cash equivalents and restricted cash as of Sept. 30. Alto gave it in its third-quarter earnings release on Nov. 10. ALTO-207, the company's lead program for treatment-resistant depression, is in late-stage clinical development.

The quarterly net loss was $25.1 million, or $0.54 a share. That is up 77.2% from $14.2 million, or $0.52 a share, in the third quarter of 2025, by OptimistFi's calculation.

In July, Alto sold 3,776,436 shares at $26.48 a share in an underwritten registered direct offering. Gross proceeds were $100.0 million and net proceeds were about $94.6 million. Alto plans to use the money to speed up and expand ALTO-207 development, including the PACE-3 trial, and for general working capital.

Key numbers

Metric	Latest	Change	Source
Cash, cash equivalents and restricted cash (vs. Dec. 31, 2025)	$319.8 million	from $177.0 million, +$142.86 million	Calculated from SEC 8-K
July registered direct offering, gross proceeds	$100.0 million		SEC 8-K Exhibit 99.1
Third-quarter net loss	$25.1 million	from $14.2 million, +77.2%	Calculated from SEC 8-K
Third-quarter research and development expenses	$18.2 million	from $10.5 million, +72.6%	Calculated from SEC 8-K
Third-quarter general and administrative expenses	$9.1 million	from $4.4 million, +104.8%	Calculated from SEC 8-K

Read more: Alto Neuroscience (ANRO) company research

Why it matters

For a holder, the filing shows a company that has bought time and is spending faster. Cash, cash equivalents and restricted cash rose $142.86 million from $177.0 million at Dec. 31, 2025, by OptimistFi's calculation from the balance sheet data.

Holders also carry more shares. Weighted-average shares outstanding were 46.5 million in the third quarter, up from 27.1 million a year earlier.

OptimistFi has argued that Alto works only if its neurobiology-based personalization improves clinical-trial odds before cash burn forces unfavorable dilution. The runway guidance eases the cash half of that test and strengthens the funding case. It leaves the trial half open.

The runway is management's expectation. The filing warns that Alto's runway projections may be wrong, or that the business may need more cash than expected.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

Where the spending went

Both cost lines rose. Research and development expenses were $18.2 million, up 72.6% from $10.5 million a year earlier. Alto said the rise was mainly from costs of the ALTO-207 PACE program.

General and administrative expenses were $9.1 million, more than double the $4.4 million of a year earlier. Alto said the rise was mainly from higher headcount and related personnel costs.

Interest income of $2.6 million, up from $1.5 million, offset part of the rise. For the first nine months of 2026, the net loss was $79.0 million, compared with $47.1 million in the same period of 2025.

The 2027 data calendar

The cash has to carry several readouts. PACE-1 is a Phase 2b trial of ALTO-207 in adjunctive treatment-resistant depression. It is targeting about 178 adults, with topline data expected in the second half of 2027.

Alto expects to start PACE-2, a Phase 3 adjunctive trial, in early 2027, pending FDA alignment on trial design. PACE-3, a Phase 3 monotherapy trial, is expected to start in the second half of 2027, also pending FDA alignment.

Phase 2b trials of ALTO-300 in major depressive disorder and ALTO-100 in bipolar depression are still enrolling. Topline data are expected in the first half of 2027 for ALTO-300 and mid-2027 for ALTO-100.

What's next

Alto expects to report the outcome of its FDA interaction and Phase 1 topline data on the modified-release formulation of ALTO-207 in late 2026 or early 2027, following FDA feedback. It will also report blinded PACE-1 safety results. Alto says the data are meant to inform final dose selection for the Phase 3 trials.

FDA alignment on trial design is the condition Alto attaches to the early-2027 start of PACE-2. Management will also present at the Stifel 2026 Healthcare Conference on Nov. 11 at 8:00 a.m. ET and the Jefferies London Healthcare Conference on Nov. 19 at 9:30 a.m. GMT.

More from OptimistFi

• ANRO stock: research and coverage of Alto Neuroscience
• Stock research on every company OptimistFi covers

From OptimistFi Perps